Search - tctmd.com

Displaying 61 - 80 of 20416

Sort: Relevancy | Date

Presentation THT 2026

How Will Guideline Committees View Results From RWE Trials?

Presenter: Paul Heidenrich

March 04, 2026

Presentation THT 2026

AHA and C3TN Shock Networks

Presenter: Shashank Shekhar Sinha

March 04, 2026

Presentation THT 2026

Cardiogenic Shock Working Group: Triumphs and Tribulations

Presenter: Rachna Kataria

March 04, 2026

Presentation THT 2026

Hemodynamic Frontiers in Heart Failure (HF2) Registry: Goals and Achievements

Presenter: Tom Heywood

March 04, 2026

Presentation THT 2026

Virtual Randomized Clinical Trials: Learnings From DANLOGIC-HF

Presenter: Tor Biering-Sørensen

March 04, 2026

Presentation THT 2026

Statistical Approaches for Developing Credible Evidence of Safety and Effectiveness for HF Devices From Real World Data: An Overview for the Clinician

Presenter: Issa Dahabreh

March 04, 2026

Presentation THT 2026

Real World Databases: What Is Required for Their Use To Substitute for Randomized Trials for Device Approvals, Reimbursement and Label Expansion

Presenter: Robert W. Yeh

March 04, 2026

Presentation THT 2026

Time for a Separate Guideline Path for HF Devices?

Presenter: Javed Butler

March 04, 2026

Presentation THT 2026

Clinical Feasibility Study of the Magenta Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in Patients with Cardiogenic Shock (ELEVATE™ CS FIH)

Presenter: David Israeli

March 04, 2026

Presentation THT 2026

Revisiting Surrogate Endpoints in Clinical Trials of HF Devices

Presenter: James Januzzi

March 04, 2026

Presentation THT 2026

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Presenter: Gregg W. Stone

March 04, 2026

Presentation THT 2026

Revisiting Patient Reported Outcomes — Can they Be Improved for Device Trials and Account for Mortality?

Presenter: John A. Spertus

March 04, 2026

Presentation THT 2026

The Path Most Traveled: An Overview of the Breakthrough Device Designation — Can It Be Improved?

Presenter: JoAnn Lindenfeld

March 04, 2026

Presentation THT 2026

Beyond Survival: Defining Success After Total Artificial Heart Implantation

Presenter: Andre Simon

March 04, 2026

Presentation THT 2026

Serial Echocardiography After Greater Splanchnic Nerve Ablation In Hfpef Demonstrates Reductions In LV Filling Pressures In Clinical Responders But Not In Nonresponders: 12 Month Follow Up In The REBALANCE-HF Trial

Presenter: Sheldon E. Litwin

March 04, 2026

Presentation THT 2026

Design and Conduct of the INNOVATE Trial: Randomizing Durable LVAD Therapy in a High-Acuity Era

Presenter: Francis D. Pagani

March 04, 2026

Presentation THT 2026

The Effects Of Istaroxime In Patients With Acute Heart Failure (AHF) And Cardiogenic Shock (CS) – Combined Analysis Of 5 Phase 2 Placebo Controlled Clinical Trials

Presenter: Beth A. Davison

March 04, 2026

Presentation THT 2026

Physiology and Hemodynamics of Left Atrial to Coronary Sinus Shunting: Potential Implications for Clinical Effectiveness

Presenter: Ryan J. Tedford

March 04, 2026

Presentation THT 2026

Impella-Bridge Strategy Tended To Be Associated With Lower Mortality Following Durable Left Ventricular Assist Device Implantation In Japan

Presenter: Makiko Nakamura

March 04, 2026

Presentation THT 2026

The Highly Dynamic Nature Of Diuretic Response In Acute Heart Failure: Insights From The FASTR Trial

Presenter: Jeffrey Testani

March 04, 2026

Advertisement

How Will Guideline Committees View Results From RWE Trials?

AHA and C3TN Shock Networks

Cardiogenic Shock Working Group: Triumphs and Tribulations

Hemodynamic Frontiers in Heart Failure (HF2) Registry: Goals and Achievements

Virtual Randomized Clinical Trials: Learnings From DANLOGIC-HF

Statistical Approaches for Developing Credible Evidence of Safety and Effectiveness for HF Devices From Real World Data: An Overview for the Clinician

Real World Databases: What Is Required for Their Use To Substitute for Randomized Trials for Device Approvals, Reimbursement and Label Expansion

Time for a Separate Guideline Path for HF Devices?

Clinical Feasibility Study of the Magenta Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in Patients with Cardiogenic Shock (ELEVATE™ CS FIH)

Revisiting Surrogate Endpoints in Clinical Trials of HF Devices

The Elephant in the Room: How To Deal With PROs in Non-Sham Controlled Studies

Revisiting Patient Reported Outcomes — Can they Be Improved for Device Trials and Account for Mortality?

The Path Most Traveled: An Overview of the Breakthrough Device Designation — Can It Be Improved?

Beyond Survival: Defining Success After Total Artificial Heart Implantation

Serial Echocardiography After Greater Splanchnic Nerve Ablation In Hfpef Demonstrates Reductions In LV Filling Pressures In Clinical Responders But Not In Nonresponders: 12 Month Follow Up In The REBALANCE-HF Trial

Design and Conduct of the INNOVATE Trial: Randomizing Durable LVAD Therapy in a High-Acuity Era

The Effects Of Istaroxime In Patients With Acute Heart Failure (AHF) And Cardiogenic Shock (CS) – Combined Analysis Of 5 Phase 2 Placebo Controlled Clinical Trials

Physiology and Hemodynamics of Left Atrial to Coronary Sinus Shunting: Potential Implications for Clinical Effectiveness

Impella-Bridge Strategy Tended To Be Associated With Lower Mortality Following Durable Left Ventricular Assist Device Implantation In Japan

The Highly Dynamic Nature Of Diuretic Response In Acute Heart Failure: Insights From The FASTR Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content